中国临床药理学杂志2026，Vol.42Issue(5)：720-726,7.DOI:10.13699/j.cnki.1001-6821.2026.05.019
替雷利珠单抗治疗晚期非小细胞肺癌的药学监护路径构建与实践
Development and implementation of a clinical pharmacist intervention strategy for tislelizumab in the treatment of advanced non-small cell lung cancer
摘要
Abstract
Objective To construct a clinical pharmacist intervention strategy for tislelizumab injection in the treatment of advanced non-small cell lung cancer(NSCLC)and evaluate its practical effects.Methods Patients with advanced NSCLC admitted to our hospital were divided into control group and treatment group.The control group received routine pharmaceutical care,while the treatment group received a clinical pharmacist intervention strategy.Therapeutic efficacy,incidence of immune-related adverse events(irAEs),incidence of grade ≥ 3 irAEs,treatment-related drug withdrawal rate,medication adherence,quality of life and satisfaction with pharmaceutical care were compared between the two groups.Results A total of 106 patients were included,including 53 in control group and 53 in treatment group.After treatment,the objective response rates(ORR)of treatment group and control group were 47.17％and 28.30％,respectively;the disease control rates(DCR)were 60.38％and 39.62％,respectively.The above indicators in treatment group were statistically significantly higher than those in control group(all P＜0.05).The incidences of irAEs in treatment group and control group were 39.62％and 60.38％,respectively;the incidences of irAEs ≥ grade 3 were 13.21％and 30.19％,respectively;the treatment-related discontinuation rates were 9.43％and 24.53％,respectively.The above indicators in treatment group were statistically significantly lower than those in control group(all P＜0.05).After treatment,the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-lung cancer 13(EORTC QLQ-LC13)scores for treatment group and control group were(50.15±9.06)and(53.94±7.19)points,respectively,with treatment group statistically significantly lower than control group(P＜0.05).The satisfaction rate of pharmaceutical services in treatment group was 90.57％,statistically significantly higher than control group's 75.47％(P＜0.05).Conclusion The clinical pharmacist intervention strategy can improve medication adherence to tislelizumab injection,reduce immune-related adverse events and treatment interruption,improve quality of life,and enhance satisfaction with pharmaceutical care,thereby contributing to better clinical outcomes.关键词
替雷利珠单抗注射液/肺癌/药学监护/生活质量Key words
tislelizumab injection/lung cancer/clinical pharmacist intervention strategy/quality of life分类
医药卫生引用本文复制引用
刘莫愁,姜道利,季磊..替雷利珠单抗治疗晚期非小细胞肺癌的药学监护路径构建与实践[J].中国临床药理学杂志,2026,42(5):720-726,7.基金项目
江苏省高校重点实验室开放课题基金资助项目(XZSYSKF2024015) （XZSYSKF2024015）
